yes, a lot of potential downside too, although not as much as Elan stil has tysabri. anyway, there are ways to protect the downside.
"But the subsequent biomarker data has been very good. Bapineuzumab has now been shown to remove amyloid and to reduce phosphotau.
--------------------------------------------------------------------------------
There's still no evidence that either of these feats provides any concrete benefits to AD patients, though, is there?"
there's no concrete evidence, but scientifically, its hard to argue that removing amyloid and especially reducing ptau will not be beneficial to the patients. However, i do think they need to be treated earlier and longer.
it took awhile to provide that lowering cholesterol would reduce heart disease
